Drugs / PF-04764793
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01272375 | Jan → May 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00928278 | Jul → Oct 2009 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00977015 Comparator | Sep → Nov 2009 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04764793 | “The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.” NCT01272375 ↗ |
| Route | Inhaled | “Inhaled, 300/150, single dose” NCT00928278 ↗ |